Abbonarsi

Association between Pan-immune-inflammation value and in-hospital mortality in critically ill patients with Chronic obstructive pulmonary disease: An observational study - 02/07/25

Doi : 10.1016/j.rmed.2025.108213 
Mohan Giri a, , 1 , Anju Puri b, 1, Yi Chen a, Yan Liu a, Shuliang Guo a
a Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing, 400016, China 
b Department of Nursing, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing, 400016, China 

Corresponding author.

Abstract

Objective

This study aimed to examine the relationship between the pan-immune inflammation value (PIV) and mortality in critically ill patients with chronic obstructive pulmonary disease (COPD), highlighting its potential as a prognostic tool for this high-risk group.

Methods

This retrospective cohort study utilized data from the MIMIC-IV 2.2 database. Participants were stratified into tertiles based on their PIV levels, with the primary endpoint being in-hospital mortality. Cox proportional hazards regression models were used to analyze the association between PIV and mortality, and Kaplan-Meier survival curves illustrated survival differences among PIV tertiles. Subgroup analyses and interaction tests ensured the robustness of the findings.

Results

A total of 3259 critically ill COPD patients were included. The in-hospital and 90-day mortality rates were 15 % and 27.6 %, respectively. Multivariate analysis showed that higher PIV levels were significantly associated with increased in-hospital (HR: 1.08, 95 % CI: 1.02–1.14, P = 0.012) and 90-day mortality (HR: 1.16, 95 % CI: 1.11–1.21, P < 0.001). Patients in the highest tertile of PIV (T3) had a significantly higher risk of mortality compared to those in the lowest tertile (T1). The trend test across tertiles demonstrated a positive association between PIV and mortality risk in all models (P for trend <0.001). Subgroup analyses revealed no significant effect modification except for gender and liver disease.

Conclusion

Elevated baseline PIV was independently associated with higher mortality risks in critically ill COPD patients, suggesting its potential as a simple, reliable, and cost-effective prognostic indicator for high-risk patients.

Il testo completo di questo articolo è disponibile in PDF.

Highlights

This is the first and most extensive study assessing the link between PIV and mortality in critically ill COPD patients.
•Elevated PIV is significantly associated with increased in-hospital and 90-day all-cause mortality in COPD patients.
•The study utilizes the MIMIC-IV database, involving 3259 critically ill patients, ensuring clinical relevance and statistical power.
•PIV is a cost-effective, simple biomarker derived from routine CBC tests, valuable for risk stratification in critically ill COPD patients.
•Findings suggest PIV as a practical tool for improving clinical decision-making and patient outcomes in ICU settings.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Chronic obstructive pulmonary disease, Critically ill, Inflammation, MIMIC-IV database, Mortality, Pan-immune inflammation value


Mappa


© 2025  Elsevier Ltd. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 245

Articolo 108213- agosto 2025 Ritorno al numero
Articolo precedente Articolo precedente
  • Ethnic variation in South East Asian patients with severe asthma: A first look at the Singapore Severe Asthma Registry (SSAR) and implications on clinical practice
  • Tunn Ren Tay, Pee Hwee Pang, Mei Fong Liew, Pei Yee Tiew, Mon Hnin Tun, Tavleen Kaur Jaggi, Anna Lau, Hui Fang Lim, Genevieve Tan, Nicole Yu-Fang Sieow, Sanjay H. Chotirmall, Mariko Siyue Koh
| Articolo seguente Articolo seguente
  • ICS use trajectories in severe asthma patients on benralizumab: real-life data from 3-years follow-up
  • Laura Pini, Marco Caminati, Matteo Maule, Diego Bagnasco, Bianca Beghè, Benedetta Bondi, Fulvio Braido, Paolo Cameli, Cristiano Caruso, Claudia Crimi, Yehia El Masri, Jordan Giordani, Gabriella Guarnieri, Manuela Latorre, Andrea Mastrototaro, Francesco Menzella, Claudio Micheletto, Alessandro Pini, Stefano Piras, Antonio Spanevello, Andrea Vianello, Dina Visca, Martina Zappa, Marco Zurlo, Pierluigi Paggiaro, Francesco Blasi, Giorgio Walter Canonica, Gianenrico Senna, Roberto Benoni, SANI study group

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.